EN DE

UMP Healthcare Holdings (0722) Fair Value & Analysis

Healthcare · HK · Market cap HK$369M

UH UMP Healthcare Holdings 0722 · HK
PriceHK$0.4450
Fair ValueHK$0.8500
Upside+91.0%
Quality68/100
Watch UMP Healthcare Holdings for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Thin margins · 4.4% net margin
generates free cash flow
7.10% dividend yield
Ranks above peers (8/13)
Narrow moat 36/100
Evidence: High Range HK$0.6400 – HK$1.07 Share as image

Fair value as of: Aug 13, 2026

From 26 valuation models · updated 2 days ago

Share price −1.1% over the past month.

A solid business, screening 91% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (HK$0.6400). The market is more pessimistic than our downside scenario.
  • Solid quality (68/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$1.33 HK$0.3571 Fair Value HK$0.8500 Sep 2019 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$0.3571 – HK$1.33 · fair‑value band HK$0.6400 – HK$1.07 · the HK$0.4450 price screens below the HK$0.8500 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

UMP Healthcare Holdings (0722) currently trades at HK$0.4450, while our model-based Fair Value estimate is HK$0.8500, implying the stock looks roughly 91.0% undervalued today. The Quality Score stands at 68/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, UMP Healthcare Holdings generated revenue of HK$724M at a net margin of 4.4%. Revenue declined 1.0% year over year. It earns a return on equity of 4.4%. The balance sheet holds a net cash position of HK$141M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.6400 (bear case) to HK$1.07 (bull case); at HK$0.4450, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 10% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at 91%, 0722 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income HK$0.6500 HK$0.6500 HK$0.5600 76
Growth DCF HK$1.92 HK$2.49 HK$3.21 72
Gordon GGM HK$0.2600 HK$0.4800 HK$0.6600 70
All 26 models by family
DCF Models
FCF DCF HK$1.91 HK$2.57 HK$3.43 38
Owner Earnings HK$1.81 HK$2.43 HK$3.25 31
5Y Revenue Exit HK$2.05 HK$3.03 HK$4.26 39
5Y EBITDA Exit HK$3.20 HK$5.16 HK$7.43 41
5Y P/E Exit HK$1.33 HK$1.68 HK$2.04 38
10Y Revenue Exit HK$1.93 HK$2.75 HK$3.83 36
10Y EBITDA Exit HK$2.64 HK$4.09 HK$6.01 37
10Y P/E Exit HK$1.55 HK$1.90 HK$2.29 35
Earnings-Based
Graham-Dodd HK$0.2600 HK$0.7900 HK$1.04 54
Lynch FV HK$0.1700 HK$0.2400 HK$0.3100 50
PEG = 1.0 HK$0.1700 HK$0.2400 HK$0.3100 46
EPV HK$2.31 HK$2.58 HK$2.80 59
Dividend Discount
Gordon GGM HK$0.2600 HK$0.4800 HK$0.6600 70
DDM Multi-Stage HK$0.2600 HK$0.4000 HK$0.5100 61
Multiples
P/E Multiple HK$0.6400 HK$0.8500 HK$1.07 63
P/S Multiple HK$0.4900 HK$0.6600 HK$0.8200 58
P/B Multiple HK$0.4900 HK$0.6600 HK$0.8200 55
EV/EBIT HK$3.80 HK$4.95 HK$6.09 53
EV/EBITDA HK$4.57 HK$5.97 HK$7.37 54
EV/Revenue HK$2.26 HK$3.06 HK$3.87 43
Asset-Based
NCAV (Graham) HK$0.4600 HK$0.6100 HK$0.9200 50
Growth DCF
Growth DCF HK$1.92 HK$2.49 HK$3.21 72
Rev-Margin DCF HK$2.05 HK$3.03 HK$4.15 67
Economic Profit
Residual Income HK$0.6500 HK$0.6500 HK$0.5600 76
ROIC Compounder HK$2.39 HK$2.77 HK$3.14 67
Growth Earnings
Growth-Adj P/E HK$0.5200 HK$0.7400 HK$0.9600 68

Widest divergence: DCF Models (HK$2.57) versus Earnings-Based (HK$0.2400). Highest evidence: Residual Income (76).

Notify me when 0722 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$724M
Revenue growth (YoY) -1.0%
Net margin 4.4%
Return on equity 4.4%
Free cash flow HK$134M FY2025
P/E ratio 11.1
More key figures
Operating margin 6.3%
EPS (TTM) HK$0.0400
Dividend yield 7.1%
EPS growth (YoY) +5.1%
Net cash HK$141M FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 68/100

Of which business quality 70 · Market factors (momentum, volatility) 53

Profitability 43
Margins and returns on capital today
Quality Growth 19
Are margins and returns improving?
Cashflow 86
Earnings quality: real cash, not paper profit
Fin. Strength 94
Balance sheet, leverage, solvency risk
Investment 94
Disciplined investing over empire-building
Low Volatility 83
Calm price path (market factor)
Momentum 43
Price trend over the last 3–12 months (market factor)
52W Momentum 36
Distance to the 52-week high (market factor)
Net Issuance 85
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

UMP Healthcare Holdings Limited, an investment holding company, provides a range of medical and healthcare services in Hong Kong, Macau, and Mainland China. It operates in three segments, Hong Kong & Macau Corporate Healthcare Solution Services, Hong Kong & Macau Clinical Healthcare Services, and Chinese Mainland Clinical Healthcare Services.

Full company description

UMP Healthcare Holdings Limited, an investment holding company, provides a range of medical and healthcare services in Hong Kong, Macau, and Mainland China. It operates in three segments, Hong Kong & Macau Corporate Healthcare Solution Services, Hong Kong & Macau Clinical Healthcare Services, and Chinese Mainland Clinical Healthcare Services. The company offers general practice and family medicine; specialist consultation services, including internal medicine, surgery, pediatrics, cardiology, dermatology, otorhinolaryngology, orthopedics, ophthalmology, urology, gastroenterology and hepatology, radiology, endocrinology, and diabetes; and dental care services, such as dental implant, cosmetic dentistry, periodontal treatments, and orthodontics, as well as traditional Chinese medicines. It also provides physiotherapy services comprising muscle-strengthening, limb function, eye-hand coordination, and hand function trainings; day surgery and endoscopy; diagnostic imaging and laboratory; preventive medicines and health assessment; visa medical examination; vaccination and consultation; vision care and optometry; plastic, head, and neck surgeries; medical and cosmetics dermatology, and aesthetics; chronic disease management, such as hypertension, cardiovascular disease, diabetes, and joint diseases; and corporate healthcare solutions and third party administration services. In addition, the company offers WeWell Healthcare, a health service platform for family health management, recommending, and arranging professional medical and health services for each family member, including health checkup, vaccinations, and other specialist medical services referrals, etc. Further, it provides specialist consultation services. It serves insurance companies and corporations, and self-paid patients. The company was founded in 1990 and is based in Central, Hong Kong.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

UMP Healthcare Holdings reported revenue of HK$727M in FY2025 versus HK$617M in FY2021, a compound +4.2%/yr. Reported net income was HK$31.4M in FY2025, compounding −2.5%/yr from FY2021.

Growth Quality 64/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
HK$727M
Latest YoY
−2.8%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.0%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+5.4%
Avg. growth/yr (12Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.1%
Revenue +4.2%/yr
FY21 HK$617M
FY22 HK$666M
FY23 HK$728M
FY24 HK$748M
FY25 HK$727M
Net income −2.5%/yr
FY21 HK$34.8M
FY22 HK$72.2M
FY23 HK$60.5M
FY24 HK$40.6M
FY25 HK$31.4M
Character of growth · EPS growth decomposed (2014-2025) +1.0 % p.a.
Revenue per share +3.4 pp

of which total revenue +6.9 pp · buybacks/dilution −3.5 pp

EBIT margin +2.1 pp
Tax rate +0.6 pp
Residual (interest, one-offs) −5.0 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch 0722: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

UMP Healthcare Holdings · Fair Value
HK$0.8500 +91%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "UMP Healthcare Holdings Fair Value". https://www.fairvalue-calculator.com/stock/0722

Peer Group

Medical Care Facilities · 265 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 68 · Top 25%
Fair Value upside +91% · Top 25%
Return on equity (TTM) 4% · Below median
Return on assets 2% · Below median
Net margin (TTM) 4% · Below median
Operating margin (TTM) 6% · Below median
Revenue growth -1% · Below median
Dividend yield (TTM) 7.1% · Top 25%

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/E (TTM) 11.1× · Cheaper than 75% of peers
P/B 0.50× · Cheaper than 75% of peers
P/S (TTM) 0.51× · Cheaper than 75% of peers
P/FCF 0.4× · Cheaper than 75% of peers
EV/EBITDA 0.8× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 26
FUTURE 0 · sector 24
PAST 18 · sector 30
HEALTH 0 · sector 90
DIVIDEND 100 · sector 41

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $414.59 $547.67 +32%
Fresenius SE FRE €46.82 €32.15 -31%
Dr. Sulaiman Al Habib Medical Services Group 4013 235.00 SAR 112.37 SAR -52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.67 SGD 1.44 SGD -46%
Tenet Healthcare Corporation THC $266.79 $330.25 +24%
Rede D'Or São Luiz S.A RDOR3 R$33.97 R$47.31 +39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,565 ₹2,955 -65%
Aier Eye Hospital Group 300015 ¥8.87 ¥7.67 -14%
Max Healthcare Institute Limited MAXHEALTH ₹1,008 ₹284.87 -72%
Bangkok Dusit Medical Services Public Company BDMS 19.70 THB 18.57 THB -6%

Compare UMP Healthcare Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is UMP Healthcare Holdings (0722) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$0.8500 versus a price of HK$0.4450, about +91% (undervalued).
What is the fair value of 0722?
Our model-based fair value for UMP Healthcare Holdings is HK$0.8500 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$0.4450.
What is the quality score of 0722?
UMP Healthcare Holdings has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of UMP Healthcare Holdings (0722)?
UMP Healthcare Holdings reported trailing-twelve-month revenue of about HK$724M (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 0722?
The net profit margin of UMP Healthcare Holdings is about 4.4%, meaning it keeps roughly 4.4% of revenue as net income. Based on the latest reported figures.
Does UMP Healthcare Holdings pay a dividend?
UMP Healthcare Holdings currently shows a dividend yield of about 7.10% relative to its recent price (as of Aug 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track UMP Healthcare Holdings and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.